Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Business Wire•14/10/2026•06:45 ET
0
Key Highlights
- ➤57 abstracts span Pfizer’s infectious-disease pipeline and portfolio at IDWeek 2026
- ➤25-valent pneumococcal vaccine candidate advances ongoing pediatric Phase 3 program
- ➤Phase 3 VALOR results support Pfizer-Valneva Lyme vaccine candidate’s antibody-associated protection
- ➤ABRYSVO real-world studies support effectiveness in older adults and infants
- ➤PREVNAR 20 real-world data show reductions in invasive pneumococcal disease and pneumonia
Expert Statements
Annaliesa Anderson, Senior Vice President and Chief Vaccines Officer, Pfizer
“At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies that protect and treat people today while pursuing innovations to expand their impact in the future. Our data at IDWeek 2026 reflects this commitment, with real-world and clinical data across our portfolio as well as important clinical milestones for our next-generation pediatric pneumococcal vaccine candidate and registrational Lyme vaccine candidate. Through these efforts, we are translating scientific advancements into meaningful benefits for communities around the world.”
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV
Get started
Create a free account to read the full story.